Stocks Perrigo Corporation Limited

More

  • Some of the names on the move ahead of the open.

  • Some of the names on the move ahead of the open.

  • Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline.

  • Some of the names on the move ahead of the open.

  • Boston, April 15: Women desperate to hear from loved ones

    In the aftermath of the Boston Marathon explosions, counterterrorism officials have found what they believe to be five additional, undetonated explosive devices around the Boston area.

  • Boston, April 15: Women desperate to hear from loved ones

    In the aftermath of the Boston Marathon explosions, counterterrorism officials have found what they believe to be five additional, undetonated explosive devices around the Boston area.

  • European shares closed lower on Monday, after news of an unexpected slowdown in China sparked a commodities sell-off.

  • Some of the names on the move ahead of the open.

  • Some of the names on the move ahead of the open.

  • Mathew Martoma

    Hedge fund advisory firm CR Intrinsic Investors has agreed to pay the SEC a record $600 million-plus to settle insider trading charges.

  • Some of the names on the move ahead of the open.

  • elan.jpg

    Irish drugmaker Elan has sweetened the terms on offer to shareholders under its $3.25 billion disposal plan, as it aims to stave off an approach for the company from U.S. investment firm Royalty Pharma.

  • The pharmaceutical and biopharmaceutical sectors have been marching steadily higher. TheStreet.com reports on two stocks with potential to appreciate.

  • elan.jpg

    Royalty Pharma has made a $6.6 billion bid to buy Elan, seeking to scupper the drugmaker's plan to spend most of the proceeds from a major drug sale on deals.

  • Some of the names on the move ahead of the open.

  • Steven A. Cohen, Founder and CEO of SAC Capital.

    An investor reckons that he is a victim of alleged insider trading at SAC Capital. And while he certainly lost a lot of money, SAC had nothing to do with it.

  • Steven A. Cohen, Founder and CEO of SAC Capital.

    Internal trading records raise questions on whether the government will be able to build a case against Steven A. Cohen, the billionaire owner of the hedge fund.

  • SAC Capital Advisors expects client withdrawals of at least $1 billion in 2013 as the hedge fund battles intense regulatory scrutiny over insider trading allegations, the Wall Street Journal said on Friday, citing people briefed on the matter.

  • Elan Corp. PLC reported a third-quarter loss Wednesday, as heavy charges tied to a business spinoff and the discontinuation of an Alzheimer's drug study weighed on the Irish drugmaker's performance.

  • In a story Oct. 16 on Johnson& Johnson's third-quarter results, The Associated Press reported that J&J would take a $340 million charge for ending testing of the intravenous form of Alzheimer's disease drug bapineuzumab and said that J&J's partner, Pfizer Inc., would be taking a similar charge.